-+ 0.00%
-+ 0.00%
-+ 0.00%

Bristol-Myers Squibb: A phase III ALOFT-IPF trial evaluating ADMILPARANT for treating idiopathic pulmonary fibrosis in adults reached a major end.

智通財經·10/12/2026 10:57:22
語音播報
Bristol-Myers Squibb: A phase III ALOFT-IPF trial evaluating ADMILPARANT for treating idiopathic pulmonary fibrosis in adults reached a major end.